$75.6 Million is the total value of Qiming U.S. Ventures Management, LLC's 7 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ICOSAVAX INC | $27,871,210 | +151.3% | 3,510,228 | 0.0% | 36.87% | +128.8% | ||
| VENTYX BIOSCIENCES INC | $24,473,472 | -6.1% | 746,370 | 0.0% | 32.37% | -14.5% | ||
| HILLEVAX INC | $9,350,782 | -2.1% | 558,923 | 0.0% | 12.37% | -10.9% | ||
| KZR | KEZAR LIFE SCIENCES INC | $5,834,125 | -18.2% | 828,711 | 0.0% | 7.72% | -25.5% | |
| TALS | TALARIS THERAPEUTICS INC | $2,991,258 | -61.2% | 2,932,606 | 0.0% | 3.96% | -64.7% | |
| JASPER THERAPEUTICS INC | $2,826,405 | -38.8% | 5,852,982 | 0.0% | 3.74% | -44.3% | ||
| ELEV | ELEVATION ONCOLOGY INC | $2,251,635 | -15.9% | 2,370,142 | 0.0% | 2.98% | -23.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-01-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
| KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
| ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
| HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.